Comparative Pharmacology
Head-to-head clinical analysis: CALCIPARINE versus PANHEPRIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CALCIPARINE versus PANHEPRIN.
CALCIPARINE vs PANHEPRIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Unfractionated heparin (UFH) potentiates antithrombin III (ATIII) activity, leading to inhibition of factor Xa and thrombin (factor IIa). It also binds to heparin cofactor II, inhibits platelet aggregation, and increases vascular permeability.
Heparin binds to antithrombin III, causing a conformational change that accelerates the inactivation of thrombin (factor IIa) and activated factor X (factor Xa), thereby inhibiting blood coagulation.
5000 IU subcutaneously twice daily for prophylaxis; 5000 IU intravenous bolus followed by 800-1000 IU/hour continuous intravenous infusion for treatment.
80 units/kg IV bolus followed by 18 units/kg/hour continuous IV infusion; adjust to maintain aPTT 1.5-2.5 times control.
None Documented
None Documented
Terminal elimination half-life is approximately 1.5 hours (subcutaneous) after a 5000 IU dose. With therapeutic doses (e.g., 15,000 IU/24h), half-life may prolong to 2-3 hours. Clinical context: Half-life is dose-dependent and increases with heparin clearance saturation.
Terminal elimination half-life is dose-dependent: at standard IV doses (100 U/kg), mean t½ = 60 min (range 40–90 min); at high doses (400 U/kg), t½ increases to 150 min due to saturable clearance mechanisms. Clinical context: Short t½ necessitates continuous infusion or frequent subcutaneous dosing for sustained anticoagulation.
Primarily renal, with 40-60% of the dose excreted unchanged in urine. Minor biliary/fecal elimination (<10%).
Primarily renal excretion of metabolites (desulfated heparin) with a minor biliary/fecal component. Unchanged heparin is not excreted renally; clearance occurs via saturable hepatic metabolism and reticuloendothelial system uptake. Renal excretion accounts for approximately 50% of total clearance at therapeutic doses, while biliary/fecal elimination is <10%.
Category C
Category C
Anticoagulant
Anticoagulant